SELLAS Life Sciences Group, Inc. (SLS)

14.09USD -1.67% (-0.24)

Over 3Y: +852.0%

2026-08-25
5 10 15
2023 2024 2025 2026

Figures as at 2023-12-31, reported in USD. The newest fact in the filings is dated 2026-06-30, 57 days ago. Nothing on this page is advice.

How it scores

Five questions, each answered by the measures under it. Every figure is the company's own; the bar beside it is where that figure sits among the companies read here — the top fifth, the bottom fifth, or somewhere between. Not among all listed companies, and for a valuation multiple the low end is the good end.

Durability

How predictable is the revenue, and how much of it is already committed?

1.0

Resilience

Can the balance sheet absorb a bad year?

10.0
ND/EBITDA 0.051
Current ratio 18.8×

Growth

Is the business getting bigger, and is it getting more profitable?

1.0
Sales/sh Y/Y -100.0%

A measure absent from a block could not be computed from this company's filings. It is left out rather than scored as though it were bad, and the dimension is averaged over what remains. A score is measured against a fixed scale this model states; the bar is measured against the other companies, so the two can disagree — and where they do, that disagreement is the more interesting figure.

Revenue by fiscal year

As the company reported it, one row per year, straight from the filings.

Fiscal yearEndsRevenue
20122012-12-31 0
20132013-12-31 2,487,000
20142014-12-31 9,319,000
20192019-12-31 0
20202020-12-31 1,900,000
20212021-12-31 7,600,000
20222022-12-31 1,000,000
20232023-12-31 0

The ratios

The figures themselves rather than their scores — what somebody looking up SLS on one particular measure came for.

RatioValue
current ratio18.83
current ratio reported18.83
deferred revenue growth-100.0
growth cv3.26
revenue growth-100.0
revenue growth per share-100.0
rpo growth0.0

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 0 PaymentsToAcquirePropertyPlantAndEquipment 2016-12-31
cash 138,343,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 142,505,000 AssetsCurrent 2026-06-30
current liabilities 7,569,000 LiabilitiesCurrent 2026-06-30
equity 137,656,000 StockholdersEquity 2026-06-30
revenue 0 RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31
sbc 0 ShareBasedCompensation 2026-06-30

What to be careful about

See it scored yourself

The dashboard puts SLS beside other companies and lets you change what counts: the weight of each dimension, the value that earns a ten, and which of the 61 measures are included at all.